|
1
|
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
|
Cancer Cell
|
2002
|
11.83
|
|
2
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
|
3
|
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
|
Nature
|
2012
|
9.89
|
|
4
|
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
|
N Engl J Med
|
2009
|
7.95
|
|
5
|
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
|
Mol Ther
|
2009
|
6.91
|
|
6
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
|
7
|
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
|
Lancet Oncol
|
2009
|
4.89
|
|
8
|
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
|
Blood
|
2004
|
4.21
|
|
9
|
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
|
Lancet Oncol
|
2010
|
3.76
|
|
10
|
Primary B cell immunodeficiencies: comparisons and contrasts.
|
Annu Rev Immunol
|
2009
|
2.97
|
|
11
|
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.
|
Blood
|
2005
|
2.81
|
|
12
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
|
13
|
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.
|
Blood
|
2009
|
2.70
|
|
14
|
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
|
Blood
|
2012
|
2.55
|
|
15
|
Cytotoxicity of activated natural killer cells against pediatric solid tumors.
|
Clin Cancer Res
|
2010
|
2.51
|
|
16
|
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
|
Cancer Res
|
2009
|
2.37
|
|
17
|
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
|
Blood
|
2007
|
2.19
|
|
18
|
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
|
Blood
|
2012
|
2.14
|
|
19
|
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
|
J Clin Invest
|
2007
|
2.05
|
|
20
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
|
21
|
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.88
|
|
22
|
New markers for minimal residual disease detection in acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.78
|
|
23
|
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.
|
Blood
|
2002
|
1.74
|
|
24
|
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.
|
J Clin Oncol
|
2011
|
1.71
|
|
25
|
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
|
Blood
|
2013
|
1.70
|
|
26
|
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.
|
Blood
|
2011
|
1.68
|
|
27
|
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies.
|
Cytotherapy
|
2012
|
1.67
|
|
28
|
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2005
|
1.53
|
|
29
|
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
|
J Clin Oncol
|
2011
|
1.52
|
|
30
|
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.47
|
|
31
|
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
|
Blood
|
2005
|
1.42
|
|
32
|
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia.
|
Br J Haematol
|
2003
|
1.41
|
|
33
|
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
|
Blood
|
2006
|
1.41
|
|
34
|
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.
|
Blood
|
2006
|
1.40
|
|
35
|
Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
|
Br J Haematol
|
2005
|
1.35
|
|
36
|
Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase.
|
Br J Haematol
|
2003
|
1.33
|
|
37
|
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
|
J Clin Oncol
|
2014
|
1.31
|
|
38
|
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
|
Blood
|
2004
|
1.30
|
|
39
|
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
1.30
|
|
40
|
Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
|
J Clin Oncol
|
2012
|
1.29
|
|
41
|
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
|
Blood
|
2002
|
1.28
|
|
42
|
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
|
Cytotherapy
|
2012
|
1.27
|
|
43
|
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
|
PLoS One
|
2011
|
1.23
|
|
44
|
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
|
J Natl Cancer Inst
|
2011
|
1.23
|
|
45
|
Replicative potential of human natural killer cells.
|
Br J Haematol
|
2009
|
1.19
|
|
46
|
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
|
Br J Haematol
|
2010
|
1.19
|
|
47
|
Improved prognosis for older adolescents with acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
1.16
|
|
48
|
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.
|
Clin Cancer Res
|
2009
|
1.15
|
|
49
|
Synthetic messenger RNA as a tool for gene therapy.
|
Hum Gene Ther
|
2006
|
1.13
|
|
50
|
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15.
|
Br J Haematol
|
2011
|
1.10
|
|
51
|
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
|
Blood
|
2010
|
1.10
|
|
52
|
Minimal residual disease quantitation in acute myeloid leukemia.
|
Clin Lymphoma Myeloma
|
2009
|
1.07
|
|
53
|
Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group.
|
J Clin Oncol
|
2009
|
1.06
|
|
54
|
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
|
Haematologica
|
2012
|
1.05
|
|
55
|
A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
|
Cancer Res
|
2013
|
1.02
|
|
56
|
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
|
Exp Hematol
|
2007
|
1.02
|
|
57
|
Expansion and activation of natural killer cells for cancer immunotherapy.
|
Korean J Lab Med
|
2009
|
1.02
|
|
58
|
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
|
J Immunother
|
2015
|
1.01
|
|
59
|
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
|
J Pharmacol Exp Ther
|
2011
|
1.00
|
|
60
|
A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus.
|
Mol Ther Nucleic Acids
|
2013
|
0.99
|
|
61
|
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
|
Cancer
|
2013
|
0.98
|
|
62
|
Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia.
|
Haematologica
|
2006
|
0.98
|
|
63
|
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.
|
Cancer Res
|
2013
|
0.98
|
|
64
|
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
|
Cancer
|
2008
|
0.95
|
|
65
|
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
|
Pharmacogenomics
|
2011
|
0.93
|
|
66
|
Should evaluation for minimal residual disease be routine in acute myeloid leukemia?
|
Curr Opin Hematol
|
2013
|
0.92
|
|
67
|
Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing.
|
Int J Data Min Bioinform
|
2011
|
0.91
|
|
68
|
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
|
J Exp Clin Cancer Res
|
2010
|
0.90
|
|
69
|
Effect of body mass index on the outcome of children with acute myeloid leukemia.
|
Cancer
|
2012
|
0.90
|
|
70
|
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
|
Blood
|
2013
|
0.87
|
|
71
|
Treatment outcome in older patients with childhood acute myeloid leukemia.
|
Cancer
|
2012
|
0.86
|
|
72
|
Childhood acute lymphoblastic leukemia.
|
Rev Clin Exp Hematol
|
2002
|
0.86
|
|
73
|
Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy.
|
Methods Mol Biol
|
2010
|
0.86
|
|
74
|
Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies.
|
Br J Haematol
|
2011
|
0.85
|
|
75
|
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.
|
Br J Haematol
|
2014
|
0.84
|
|
76
|
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Cancer
|
2014
|
0.84
|
|
77
|
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.
|
Cancer
|
2013
|
0.82
|
|
78
|
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
|
Cytometry B Clin Cytom
|
2013
|
0.82
|
|
79
|
Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.
|
Best Pract Res Clin Haematol
|
2010
|
0.82
|
|
80
|
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
|
Int J Cancer
|
2014
|
0.81
|
|
81
|
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
|
Pharmacogenomics
|
2013
|
0.81
|
|
82
|
Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors.
|
Blood
|
2005
|
0.81
|
|
83
|
Minimal residual disease monitoring by flow cytometry.
|
Best Pract Res Clin Haematol
|
2003
|
0.80
|
|
84
|
Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells.
|
Haematologica
|
2002
|
0.80
|
|
85
|
A new method for high speed, sensitive detection of minimal residual disease.
|
Cytometry A
|
2011
|
0.80
|
|
86
|
The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report.
|
Br J Haematol
|
2012
|
0.78
|
|
87
|
Natural killer cell reprogramming with chimeric immune receptors.
|
Methods Mol Biol
|
2013
|
0.78
|
|
88
|
Minimal residual disease detection in acute lymphoblastic leukemia: real improvement with the real-time quantitative PCR method?
|
J Pediatr Hematol Oncol
|
2003
|
0.76
|
|
89
|
Definition of cure in childhood acute myeloid leukemia.
|
Cancer
|
2014
|
0.75
|
|
90
|
Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2013
|
0.75
|